227 related articles for article (PubMed ID: 28416541)
1. Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.
Jang J; Kim R; Woo M; Jeong J; Park DE; Kim G; Delorme V
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416541
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents.
Kang S; Kim YM; Jeon H; Park S; Seo MJ; Lee S; Park D; Nam J; Lee S; Nam K; Kim S; Kim J
Eur J Med Chem; 2017 Aug; 136():420-427. PubMed ID: 28527405
[TBL] [Abstract][Full Text] [Related]
3. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates.
Balganesh M; Dinesh N; Sharma S; Kuruppath S; Nair AV; Sharma U
Antimicrob Agents Chemother; 2012 May; 56(5):2643-51. PubMed ID: 22314527
[TBL] [Abstract][Full Text] [Related]
4. Structure of
Zhou S; Wang W; Zhou X; Zhang Y; Lai Y; Tang Y; Xu J; Li D; Lin J; Yang X; Ran T; Chen H; Guddat LW; Wang Q; Gao Y; Rao Z; Gong H
Elife; 2021 Nov; 10():. PubMed ID: 34819223
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203.
Kang S; Kim YM; Kim RY; Seo MJ; No Z; Nam K; Kim S; Kim J
Eur J Med Chem; 2017 Jan; 125():807-815. PubMed ID: 27750198
[TBL] [Abstract][Full Text] [Related]
6. The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd.
Lu P; Asseri AH; Kremer M; Maaskant J; Ummels R; Lill H; Bald D
Sci Rep; 2018 Feb; 8(1):2625. PubMed ID: 29422632
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis.
Kumar M; Singh K; Naran K; Hamzabegovic F; Hoft DF; Warner DF; Ruminski P; Abate G; Chibale K
ACS Infect Dis; 2016 Oct; 2(10):714-725. PubMed ID: 27737555
[TBL] [Abstract][Full Text] [Related]
8. Development of efflux pump inhibitors in antituberculosis therapy.
Song L; Wu X
Int J Antimicrob Agents; 2016 Jun; 47(6):421-9. PubMed ID: 27211826
[TBL] [Abstract][Full Text] [Related]
9. The human proton pump inhibitors inhibit
Lake MA; Adams KN; Nie F; Fowler E; Verma AK; Dei S; Teodori E; Sherman DR; Edelstein PH; Spring DR; Troll M; Ramakrishnan L
Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2215512120. PubMed ID: 36763530
[TBL] [Abstract][Full Text] [Related]
10. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis.
Hegeto LA; Caleffi-Ferracioli KR; Nakamura-Vasconcelos SS; Almeida AL; Baldin VP; Nakamura CV; Siqueira VLD; Scodro RBL; Cardoso RF
Tuberculosis (Edinb); 2018 Jul; 111():35-40. PubMed ID: 30029912
[TBL] [Abstract][Full Text] [Related]
11. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.
Adams KN; Szumowski JD; Ramakrishnan L
J Infect Dis; 2014 Aug; 210(3):456-66. PubMed ID: 24532601
[TBL] [Abstract][Full Text] [Related]
12. Efflux pump effects on
Valıyeva G; Durupınar B; Coban AY
J Chemother; 2023 Nov; 35(7):601-609. PubMed ID: 36718107
[TBL] [Abstract][Full Text] [Related]
13. Bipolar Distribution of Minimum Inhibitory Concentration of Q203 Across Mycobacterial Species.
Wang J; Jing W; Shi J; Huo F; Shang Y; Wang F; Chu N; Pang Y
Microb Drug Resist; 2021 Aug; 27(8):1013-1017. PubMed ID: 33646044
[TBL] [Abstract][Full Text] [Related]
14. Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype.
Sun Z; Xu Y; Sun Y; Liu Y; Zhang X; Huang H; Li C
Microb Drug Resist; 2014 Dec; 20(6):525-32. PubMed ID: 24940805
[TBL] [Abstract][Full Text] [Related]
15. Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.
Chen C; Gardete S; Jansen RS; Shetty A; Dick T; Rhee KY; Dartois V
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463541
[No Abstract] [Full Text] [Related]
16. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
[TBL] [Abstract][Full Text] [Related]
17. Structure of mycobacterial CIII
Yanofsky DJ; Di Trani JM; Król S; Abdelaziz R; Bueler SA; Imming P; Brzezinski P; Rubinstein JL
Elife; 2021 Sep; 10():. PubMed ID: 34590581
[TBL] [Abstract][Full Text] [Related]
18. Carvacrol activity & morphological changes in Mycobacterium tuberculosis.
Nakamura de Vasconcelos SS; Caleffi-Ferracioli KR; Hegeto LA; Baldin VP; Nakamura CV; Stefanello TF; Freitas Gauze G; Yamazaki DA; Scodro RB; Siqueira VL; Cardoso RF
Future Microbiol; 2018 Jun; 13():877-888. PubMed ID: 29877104
[TBL] [Abstract][Full Text] [Related]
19. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
Ceska Slov Farm; 2021; 70(5):164-171. PubMed ID: 35114793
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis.
Nguyen TQ; Hanh BTB; Jeon S; Heo BE; Park Y; Choudhary A; Moon C; Jang J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0044822. PubMed ID: 36321819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
